Identification of a Genomic Signature Predicting for Recurrence in Early Stage Ovarian Cancer
Abstract
The first year of the grant required: IRB approval from all the Consortium collaborative Institutions, specimen collection, inventory, initial specimen processing. All the collaborating Institutions have obtained IRB approval to identify early stage/high grade tumors from their respective pathology service and to ship these tumors together with their clinical annotations to Massachusetts General Hospital (MGH). MGH has obtained IRB approval for using these cancer FFPE samples to identify molecular features that distinguish recurrent and non-recurrent tumors through RNA sequencing. Overall we have: 1) identified 592 early-stage high-grade ovarian cancers with 5-year follow-up, clinical annotation and accurate pathological review (228 recurrent and 364 non-recurrent), 2) established a specimen repository and clinical data inventory at MGH, 3) micro-dissected and isolated RNA from 110 tumors, and 3) optimized the preparation of cDNA libraries using NuGene WT-Ovation FFPE System V2. Throughout the project we have modified the protocol for processing the tumor tissues in order to be able to isolate both RNA and DNA from each sample. This was done is response to a DoD RFA requesting research projects for secondary utilization of collected tumor specimens. The DoD has recently selected for funding the project we have described in response to this RFA.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA603977
Entities
People
- Andres Poveda
- Gunnar Kristensen
- Michael Birrer
- Tain Mcneish
Organizations
- Massachusetts General Hospital